Argenica Therapeutics Ltd has released a press release.
No Serious Safety Issues Observed in First Cohort
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007
- Argenica Receives $1.38m R&D Tax Incentive Cash Refund
- Further Positive Preclinical Results for ARG-007 In HIE
- Argenica Receives Ethics Approval To Commence Phase 1 Trial
- Appendix 4E & Annual Report 30 June 2022
Later from Argenica Therapeutics
- Safety Review Committee Approves Second Cohort
- Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial
- Safety Review Committee Approves Third Cohort Commencement
- Phase 1 Clinical Trial Progress Update
- SRC Approves Commencement Of Fourth And Final Cohort Dosing
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics